Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma
In this MEDtalk, Maria Teresa Bourlon presents the updated efficacy in the intention-to-treat population at 55-month median follow-up on the CheckMate 9ER phase 3 trial. The results show that the combination therapy with nivo+cabo continues to maintain meaningful long-term benefits in efficacy endpoints, such as progression-free survival, overall survival, and overall response rates.
